BR112014029149A2 - biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular - Google Patents

biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular

Info

Publication number
BR112014029149A2
BR112014029149A2 BR112014029149A BR112014029149A BR112014029149A2 BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2 BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2
Authority
BR
Brazil
Prior art keywords
implants
drug
magnetic resonance
vascular occlusion
eluting
Prior art date
Application number
BR112014029149A
Other languages
English (en)
Portuguese (pt)
Inventor
Chaix Celine
Thomas Meriadeg
Reb Philippe
Original Assignee
Biosphere Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosphere Medical Inc filed Critical Biosphere Medical Inc
Publication of BR112014029149A2 publication Critical patent/BR112014029149A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
BR112014029149A 2012-05-24 2013-05-23 biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular BR112014029149A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651389P 2012-05-24 2012-05-24
PCT/US2013/042363 WO2013177364A1 (en) 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Publications (1)

Publication Number Publication Date
BR112014029149A2 true BR112014029149A2 (pt) 2017-06-27

Family

ID=49621771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029149A BR112014029149A2 (pt) 2012-05-24 2013-05-23 biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular

Country Status (7)

Country Link
US (1) US10695440B2 (https=)
EP (2) EP2854869B1 (https=)
JP (1) JP6208749B2 (https=)
BR (1) BR112014029149A2 (https=)
CA (1) CA2866896C (https=)
ES (1) ES2655656T3 (https=)
WO (1) WO2013177364A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177364A1 (en) 2012-05-24 2013-11-28 Biosphere Medical, Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
JP6641265B2 (ja) 2013-09-19 2020-02-05 マイクロベンション インコーポレイテッドMicrovention, Inc. ポリマーフィルム
EP3046952B1 (en) 2013-09-19 2021-05-12 Terumo Corporation Polymer particles
EP3065719A4 (en) 2013-11-08 2017-08-09 Terumo Corporation Polymer particles
WO2016154592A1 (en) 2015-03-26 2016-09-29 Microvention, Inc. Embiolic particles
EP4279139A3 (en) 2016-09-28 2024-01-24 Terumo Corporation Polymer particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509858A (https=) 1973-06-02 1975-01-31
JPS6056676B2 (ja) 1980-07-18 1985-12-11 日立造船株式会社 コンクリ−ト複合パネル
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US6315709B1 (en) 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
KR100872884B1 (ko) 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
FR2808026B1 (fr) * 2000-04-25 2002-06-14 Alexandre Laurent Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau
JP2005053707A (ja) 2001-07-30 2005-03-03 Kankyo Device Kenkyusho:Kk 可視光応答性材料の製造方法
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
JP4909071B2 (ja) 2003-03-24 2012-04-04 プルーローメッド, インコーポレイテッド 逆感熱性ポリマーを使用する一時的な塞栓形成
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
EP2202250B1 (en) * 2004-08-19 2013-10-09 Covidien LP Water-swellable copolymers and articles and coating made therefrom
EP2229147A2 (en) * 2007-12-03 2010-09-22 The Johns Hopkins University Methods of synthesis and use of chemospheres
GB0807154D0 (en) * 2008-04-18 2008-05-21 Univ Aston Intervertebral disc
JP5792714B2 (ja) * 2009-05-28 2015-10-14 コーニング インコーポレイテッド 細胞培養のための膨潤性の合成マイクロキャリア
EP2451488A2 (en) * 2009-07-07 2012-05-16 Bartling, Sönke Multimodal visible polymer embolization material
WO2013177364A1 (en) 2012-05-24 2013-11-28 Biosphere Medical, Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Also Published As

Publication number Publication date
US20130315838A1 (en) 2013-11-28
US10695440B2 (en) 2020-06-30
EP3295961B1 (en) 2020-04-08
WO2013177364A1 (en) 2013-11-28
ES2655656T3 (es) 2018-02-21
JP2015517390A (ja) 2015-06-22
EP3295961A1 (en) 2018-03-21
EP2854869A1 (en) 2015-04-08
JP6208749B2 (ja) 2017-10-04
CA2866896C (en) 2021-01-26
EP2854869B1 (en) 2017-11-01
EP2854869A4 (en) 2015-12-30
CA2866896A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
BR112013018534A2 (pt) marcadores de mri, sistemas de entrega e extração e métodos de fabricação e uso dos mesmos
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
BR112014029149A2 (pt) biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
SG195194A1 (en) Nanogels
MX365521B (es) Polimeros que contienen zwiteriones de alto peso molecular.
CL2010000691A1 (es) Sistemas, dispositivos y/o metodos para gestionar cojinetes magneticos.
GB201113856D0 (en) Medical device
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
EP2569434A4 (en) COMPOSITIONS AND METHODS OF TREATING LEUKEMIA
IN2014DN11201A (https=)
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
IN2014DN10161A (https=)
MX344528B (es) Sistemas y metodos para determinar la idoneidad de un implante mecanico para un procedimiento medico.
BR112015023659A2 (pt) controlador e bobinas flexíveis para terapia de administração tal como para terapia contra o câncer
SG11201506260WA (en) Biodegradable metallic medical implants, method for preparing and use thereof
UY34539A (es) Heteroarilos y usos de los mismos
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
SG11201508680VA (en) New carbodiimides having terminal urea and/or urethane groups, methods for producing said carbodiimides, and use of said carbodiimides
PH12015501088A1 (en) Dimeric compounds
PH12014500686A1 (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
MX365403B (es) Peptidos y metodos para usarlos.
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
EP3579888C0 (en) ELECTROCHEMICAL GAS TRANSMITTER GENERATING COMPOSITIONS AND METHODS OF USE THEREOF AND DRESSINGS AND TREATMENT SYSTEMS INCORPORATING THE SAME

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.